Changes in human metabolites and their levels greatly reflect the results of interaction between individual genome, life styles and living environments. Metanotitia offers one of the most comprehensive metabolomics technologies worldwide directly mirroring leading-edge metabolomics platforms developed for academic research at the MPI in the group of Prof. Dr. Lothar Willmitzer. Metanotitia focus on developing metabolomics diagnostic products using body fluids such as blood and urine samples. 

    The mass spectrometry based metabolomic diagnostics have the following advantages over traditional diagnostic methods: mass spectrometry based method notably improves the specificity of detection and avoid errors and deviation in traditional detection methods (photometric assays, immunoassay on enzyme activities, detection of molecular conformation changes); introduction of stable isotopes greatly reduces the matrix effect; hundreds of target molecules can be detected simultaneously.

    Metabolomic analysis of blood (consist of endogenous metabolites) and urine samples (consist of endogenous metabolites, nutrient metabolite from food digestion or exogenous metabolites from drug intake) thus can provide us complete metabolomics data which precisely reflects individual’s metabolic status at exact time.

    These data will be combined with those obtained from common diagnostic methods (imaging diagnosis and other biomarker diagnostics) to generate complex and comprehensive data models that allow us to develop cost-efficient, non-invasive diagnostic products by liquid biopsy. Furthermore, resulting metabolomics data from different health status groups will be integrated with metadata and other clinical data to build advanced algorithms for developing early, even ultra-early disease diagnostic products which allow individuals to make accurate assessment of health risks, take early intervention and make better medical decisions on treatment.